The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global lung marker market is expected to exhibit strong growth during 2021-2026. Generally, four major types of lung markers, including EGFR, EML4-ALK, KRAS, and BRAF, are used during lung intervention procedures or lung surgeries and diagnosis. Furthermore, the markers are used to detect, diagnose, predict, and monitor the tumor, based on which the treatment is prescribed to the patient. Lung markers are only used as an additional tool to identify cancer along with several imaging tests and biopsy. Owing to this, lung markers are extensively used in thoracoscopic surgeries across hospitals, ambulatory surgical clinics, and specialty clinics, among several other healthcare facilities.
The rising demand for lung markers can be attributed to the high prevalence of respiratory disorders, such as pleural effusion, pleural mesothelioma, pleural plaque, etc., due to the increasing air pollution levels, across the globe. Besides this, the high exposure to passive smoking, along with a family history of lung cancer further drives the number of patients suffering from lung cancer, thereby augmenting the demand for lung markers. Additionally, the surging geriatric population, along with the hectic consumer lifestyles leading to a high smoking rate, further accelerate the risks of several respiratory disorders. Apart from this, the increasing healthcare expenditures by various governments for early diagnosis and pre-treatment of life-threatening diseases, such as lung cancer, are also propelling the rising utilization of lung markers at a global level. Furthermore, rising investments in several research and development activities in the field of lung cancer diagnostics and treatment is further catalyzing the demand for lung markers. In addition to this, the increasing usage of lung markers in hospitals, surgery centers, clinics, and their various applications in therapeutic purposes has also catalyzed the product demand. Looking forward, IMARC Group expects the global lung marker market to grow at a CAGR of around 11% during the forecast period (2021-2026).
Breakup by Cancer Type:
Breakup by Marker Type:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Abbott Diagnostics Ltd., Affymetrix Inc., Agilent Technologies Inc., Beckman Coulter, Fujirebio US, Hologic Inc., Roche, Siemens Healthineers, Thermo Fisher Scientific., Veridex LLC, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at